OTC · RHHBY
Healthcare · Drug Manufacturers - General
$53.19
Down-$0.19 (-0.36%)
Updated Sep 10, 2026, 11:39 PM
SID Score
5.5/10
Composite research score
Smart Money
46/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
RHHBY does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning RHHBY.
RHHBY research
Company profile and research snapshot.
ROCHE HOLDING LTD S/ADR
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 14, 2026 | TD COWEN | Hold | — |
| Jul 13, 2026 | BERENBERG | Hold | — |
| Jul 13, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
| Jul 9, 2026 | JEFFERIES | Underperform | — |
| Jun 7, 2026 | BAADER EUROPE / ALPHAVALUE | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 10, 2026
Ocugen is maintained at a Hold rating due to mixed clinical progress and ongoing pivotal trials across its ophthalmology pipeline. Click for this OCGN update.
Yahoo · Sep 10, 2026
SOUTH SAN FRANCISCO, Calif., September 10, 2026--FDA filing acceptance announced for Enspryng (satralizumab) in MOGAD, a rare neurological disease.
Yahoo · Sep 10, 2026
If approved, Enspryng would be the first and only disease-modifying therapy for MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease)Filing acceptance is based on the Phase III METEOROID study showing that Enspryng reduced the risk of relapses by 68%1 MOGAD is a rare disease of the central nervous system characterised by unpredictable attacks of the optic nerves, spinal cord or brain2,3 Basel, 10 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S.
Benzinga · Sep 10, 2026
If approved, Enspryng would be the first and only disease-modifying therapy for MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease)Filing acceptance is based on the Phase III METEOROID study showing
Interpretive context generated from the platform’s current data sources.
Roche Holding AG (RHHBY) trades at $53.38 per share with a market capitalization of approximately $318.7 billion, per SID market data. The stock exhibits notably low volatility with a beta of 0.166, indicating minimal correlation with broader market movements — a characteristic consistent with large-cap defensive healthcare names. Average daily trading volume stands at approximately 1.86 million shares, according to Massive/Polygon data. This relatively modest volume for an ADR of Roche's size reflects the stock's dual-listing dynamics, with primary liquidity concentrated on the SIX Swiss Exchange. The low beta profile positions RHHBY as a potential defensive holding during periods of heightened market turbulence, as its price movements have historically deviated significantly less than the overall market. Roche's substantial market capitalization underscores its standing as one of the largest pharmaceutical and diagnostics companies globally within the healthcare sector.
Roche Holding AG currently carries a price-to-earnings ratio of 44.08, placing it at a premium relative to many healthcare sector peers, per SID market data. The stock's price-to-book ratio stands at 8.80, reflecting the market's valuation of Roche's extensive intellectual property portfolio and diagnostics franchise. A negative PEG ratio of -1.44 suggests analysts project declining earnings growth trajectories over the forward period, according to SEC filings and consensus data. The company offers a dividend yield of approximately 3.09%, providing a meaningful income component for shareholders — a yield that ranks competitively among large-cap pharmaceutical companies. The elevated P/E multiple may reflect the market pricing in Roche's pipeline potential, including key oncology and immunology programs. However, the combination of a high earnings multiple with a negative PEG ratio indicates that the current valuation demands significant future revenue catalysts to sustain these premium levels within the healthcare sector.
Roche Holding AG registers a composite smart money score of 46 out of 100, generating a neutral signal according to SID market data. The breakdown reveals balanced but unremarkable institutional interest across multiple tracking dimensions. Insider activity scores 12.5 out of 25, reflecting limited notable insider transaction patterns in recent filings, per SEC Form 4 data. Institutional positioning scores 13.0 out of 25, suggesting moderate but not aggressive accumulation by large fund managers based on 13F institutional filings. Dark pool activity registers at 8.5 out of 25, the lowest component score, indicating relatively subdued off-exchange block trading interest in the ADR shares. Congressional trading activity scores 12 out of 25, showing no significant directional bias from disclosed congressional transactions. The overall neutral reading suggests that sophisticated market participants are neither aggressively building nor reducing positions in RHHBY at current price levels. This lack of conviction from smart money channels aligns with the stock's mixed valuation signals and defensive positioning within institutional portfolios.
Roche Holding AG has demonstrated a consistent pattern of meeting or exceeding analyst expectations across recent quarters, according to company earnings reports. In the most recent quarter ending June 2025, Roche reported EPS of 11.10 versus the consensus estimate of 10.94, delivering a positive surprise of 0.16. The prior quarter ending December 2024 showed EPS of 8.57 against estimates of 8.48, a beat of 0.09. The strongest outperformance occurred in the June 2024 quarter, where actual EPS of 10.23 exceeded the 9.34 estimate by 0.89, representing a significant upside surprise per analyst estimates. Only the December 2023 quarter showed a marginal miss, with actual EPS of 8.47 falling short of the 8.49 estimate by 0.016. The seasonal earnings pattern reveals consistently stronger first-half results compared to second-half performance, with mid-year quarters generating EPS above 10.0 while year-end quarters cluster near 8.5.
Wall Street analyst coverage of Roche Holding AG reflects a divided outlook, according to SID consensus data. In the most recent round of ratings updates through mid-July 2026, TD Cowen reiterated a Hold rating, while Berenberg maintained its Hold stance as well, per Wall Street analyst reports. Rothschild & Co Redburn reiterated a Buy recommendation, and Baader Europe/AlphaValue also maintained a Buy rating issued in early June 2026. Conversely, Jefferies reiterated an Underperform rating in July 2026, representing the bearish counterpoint among covering analysts. The distribution shows two Buy ratings, two Hold ratings, and one Underperform among the five most recent actions — none representing rating changes, as all firms maintained their prior positions. This lack of rating revisions suggests the recent earnings beat and current valuation have not materially altered analyst convictions. The split consensus reflects ongoing debate regarding whether Roche's pipeline catalysts justify the stock's elevated earnings multiple within the pharmaceutical sector.
The latest Smart Investors Daily articles mentioning RHHBY.
